PRAX
Praxis Precision Medicines, Inc.
NASDAQ · Healthcare · Biotechnology · US
$351.81
−0.94%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -29.9%
- EBIT
- -39.2%
- EPS
- -5.4%
- Free cash flow
- -60.1%
- Operating cash flow
- -60.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -31.0%
- EPS
- -17.8%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -66.1%
- EBIT
- -63.0%
- Net income
- -65.9%
- EPS
- -32.0%
- Free cash flow
- -89.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026